372 related articles for article (PubMed ID: 14697974)
21. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
22. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients.
Kornberg A; Hommann M; Tannapfel A; Wagner T; Grube T; Schotte U; Voigt R; Scheele J
Am J Transplant; 2001 Nov; 1(4):350-5. PubMed ID: 12099379
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
[TBL] [Abstract][Full Text] [Related]
24. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
Liver Transpl; 2012 Dec; 18(12):1464-70. PubMed ID: 22941516
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Nair S; Lipscomb J; Eason J
Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
[TBL] [Abstract][Full Text] [Related]
26. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.
Neff GW; Montalbano M; O'Brien CB; Nishida S; Safdar K; Bejarano PA; Khaled AS; Ruiz P; Slapak-Green G; Lee M; Nery J; De Medina M; Tzakis A; Schiff ER
Transplantation; 2004 Nov; 78(9):1303-7. PubMed ID: 15548967
[TBL] [Abstract][Full Text] [Related]
27. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
[TBL] [Abstract][Full Text] [Related]
28. Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis.
Castedal M; Felldin M; Bäckman L; Olausson M; Friman S
Transplant Proc; 2005 Oct; 37(8):3313-4. PubMed ID: 16298583
[TBL] [Abstract][Full Text] [Related]
29. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
30. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
31. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
Bizollon T; Ducerf C; Trépo C
J Hepatol; 1995; 23 Suppl 2():22-5. PubMed ID: 8720290
[TBL] [Abstract][Full Text] [Related]
32. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
33. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
34. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
Deterding K; Grüner N; Buggisch P; Wiegand J; Galle PR; Spengler U; Hinrichsen H; Berg T; Potthoff A; Malek N; Großhennig A; Koch A; Diepolder H; Lüth S; Feyerabend S; Jung MC; Rogalska-Taranta M; Schlaphoff V; Cornberg M; Manns MP; Wedemeyer H;
Lancet Infect Dis; 2013 Jun; 13(6):497-506. PubMed ID: 23523674
[TBL] [Abstract][Full Text] [Related]
35. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
[TBL] [Abstract][Full Text] [Related]
36. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Bizollon T; Adham M; Pradat P; Chevallier M; Ducerf C; Baulieux J; Zoulim F; Trepo C
Transplantation; 2005 Feb; 79(3):325-9. PubMed ID: 15699763
[TBL] [Abstract][Full Text] [Related]
37. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon.
Schmidt SC; Bahra M; Bayraktar S; Berg T; Schmeding M; Pratschke J; Neuhaus P; Neumann U
Dig Dis Sci; 2010 Jul; 55(7):2063-9. PubMed ID: 19798575
[TBL] [Abstract][Full Text] [Related]
38. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation.
De Vera ME; Smallwood GA; Rosado K; Davis L; Martinez E; Sharma S; Stieber AC; Heffron TG
Transplantation; 2001 Mar; 71(5):678-86. PubMed ID: 11292302
[TBL] [Abstract][Full Text] [Related]
39. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
Everson GT; Terrault NA; Lok AS; Rodrigo del R; Brown RS; Saab S; Shiffman ML; Al-Osaimi AM; Kulik LM; Gillespie BW; Everhart JE;
Hepatology; 2013 May; 57(5):1752-62. PubMed ID: 22821361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
